References
- Bracamonte-Baran W, Čiháková D. Cardiac autoimmunity: myocarditis. Adv Exp Med Biol. 2017;1003:187–221.
- Čiháková D, Rose NR. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol. 2008;99:95–114.
- Suzuki J, Ogawa M, Watanabe R, Morishita R, Hirata Y, Nagai R, et al. Autoimmune giant cell myocarditis: clinical characteristics, experimental models and future treatments. Expert Opin Ther Targets. 2011;15(10):1163–1172.
- Čiháková D, Sharma RB, Fairweather D, Afanasyeva M, Rose NR. Animal models for autoimmune myocarditis and autoimmune thyroiditis. Methods Mol Med. 2004;102:175–193.
- Cabigas BP, Su J, Hutchins W, Shi Y, Schaefer RB, Recinos RF, et al. Hyperoxic and hyperbaric-induced cardioprotection: role of nitric oxide synthase 3. Cardiovasc Res. 2006;1;72(1):143–51.
- Sümen G, Cimsit M, Eroglu L. Hyperbaric oxygen treatment reduces carrageenan-induced acute inflammation in rats. Eur J Pharmacol. 2001;431(2–3):265–268.
- Mychaskiw G, Pan J, Shah S, Zubkov A, Clower B, Badr A, Zhang JH. Effects of hyperbaric oxygen on skin blood flow and tissue morphology following sciatic nerve constriction. Pain Physician. 2005;8(2):157–161.
- Wilson HD, Wilson JR, Fuchs PN. Hyperbaric oxygen treatment decreases inflammation and mechanical hypersensitivity in an animal model of inflammatory pain. Brain Res. 2006;1098:126–128.
- Wilson HD, Toepfer VE, Senapati AK, Wilson JR, Fuchs PN. Hyperbaric oxygen treatment is comparable to acetylsalicylic acid treatment in an animal model of arthritis. J Pain. 2007;8(10):924–930.
- Hui J, Zhang ZJ, Zhang X, Shen Y, Gao YJ. Repetitive hyperbaric oxygen treatment attenuates complete Freund's adjuvant-induced pain and reduces glia-mediated neuroinflammation in the spinal cord. J Pain. 2013 Jul;14(7):747–58.
- Chen X, Duan XS, Xu LJ, Zhao JJ, She ZF, Chen WW, et al. Interleukin-10 mediates the neuroprotection of hyperbaric oxygen therapy against traumatic brain injury in mice. Neuroscience. 2014;266:235–43.
- Qi Z, Gao CJ, Wang YB, Ma XM, Zhao L, Liu FJ, et al. Effects of hyperbaric oxygen preconditioning on ischemia-reperfusion inflammation and skin flap survival. Chin Med J (Engl). 2013;126(20):3904–9.
- Zhang Y, Lv Y, Liu YJ, Yang C, Hu HJ, Meng XE, et al. Hyperbaric oxygen therapy in rats attenuates ischemia-reperfusion testicular injury through blockade of oxidative stress, suppression of inflammation, and reduction of nitric oxide formation. Urology. 2013;82(2):489 e9–489 e15.
- Wang C, Ye Z, Zheng J, Liu K, Sun X, Tao H, et al. Targeting reactive oxygen species by edaravone inhalation in a rat hyperoxic lung injury model: role of inflammasome. Undersea Hyperb Med. 2013;40(6):505–11.
- Wu ZS, Lo JJ, Wu SH, Wang CZ, Chen RF, Lee SS, et al. Early hyperbaric oxygen treatment attenuates burn-induced neuroinflammation by inhibiting the galectin-3-dependent toll-like receptor-4 pathway in a rat model. Int J Mol Sci. 2018;19(8):2195.
- Chen C, Chen W, Li Y, Dong Y, Teng X, Nong Z, et al. Hyperbaric oxygen protects against myocardial reperfusion injury via the inhibition of inflammation and the modulation of autophagy. Oncotarget. 2017;8(67):111522–534.
- Bo-Htay C, Shwe T, Jaiwongkam T, Kerdphoo S, Pratchayasakul W, Pattarasakulchai T, et al. Hyperbaric oxygen therapy effectively alleviates D-galactose-induced-age-related cardiac dysfunction via attenuating mitochondrial dysfunction in pre-diabetic rats. Aging (Albany NY). 2021;13(8):10955–72.
- Silva FS, de Souza KSC, Galdino OA, de Moraes MV, Ishikawa U, Medeiros MA, et al. Hyperbaric oxygen therapy mitigates left ventricular remodeling, upregulates MMP-2 and VEGF, and inhibits the induction of MMP-9, TGF-β1, and TNF-α in streptozotocin-induced diabetic rat heart. Life Sci. 2022;15;295:120393.
- Leitman M, Efrati S, Fuchs S, Hadanny A, Vered Z. The effect of hyperbaric oxygenation therapy on myocardial function. Int J Cardiovasc Imaging. 2020;36(5):833–840.
- Rabinovich GA, Liu FT, Hirashima M, Anderson A. An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity, and cancer. Scand J Immunol. 2007;66(2–3):143–158.
- Hsu DK, Chen HY, Liu FT. Galectin-3 regulates T-cell functions. Immunol Rev. 2009;230(1):114–127.
- Radosavljevic G, Volarevic V, Jovanovic I, Milovanovic M, Pejnovic N, Arsenijevic N, et al. The roles of Galectin-3 in autoimmunity and tumor progression. Immunol Res. 2012;52(1–2):100–10.
- Burguillos MA, Svensson M, Schulte T, Boza-Serrano A, Garcia-Quintanilla A, Kavanagh E, et al. Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep. 2015;10(9):1626–38.
- Kovacevic MM, Pejnovic N, Mitrovic S, Jovicic N, Petrovic I, Arsenijevic N, et al. Galectin-3 deficiency enhances type 2 immune cell-mediated myocarditis in mice. Immunol Res. 2018;66(4):491–502.
- Yu L, Ruifrok WP, Meissner M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6(1):107–117.
- Zhong X, Qian X, Chen G, Song X. The role of galectin-3 in heart failure and cardiovascular disease. Clinical and Experimental Pharmacology and Physiology. 2019; 46(3):197–203.
- Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. 2015;66:767–75.
- Yu L, Ruifrok WPT, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013; 6:107–17.
- Vergaro G, Prud'homme M, Fazal L, et al. Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. Hypertension. 2016;67:606–12.
- Hara A, Niwa M, Kanayama T, Noguchi K, Niwa A, Matsuo M, et al. Galectin-3: A Potential Prognostic and Diagnostic Marker for Heart Disease and Detection of Early Stage Pathology. Biomolecules. 2020;10(9):1277.
- Mo D, Tian W, Zhang HN, Feng YD, Sun Y, Quan W, et al. Cardioprotective effects of galectin-3 inhibition against ischemia/reperfusion injury. European Journal of Pharmacology. 2019;859:172701.
- Song X, Qian X, Shen M, et al. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. Biochim Biophys Acta. 2015;1853:513–21.
- Qian X, Li M, Wagner MB, Chen G, Song X. Doxazosin Stimulates Galectin-3 Expression and Collagen Synthesis in HL-1 Cardiomyocytes Independent of Protein Kinase C Pathway. Front Pharmacol. 2016;7:495.
- Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung WP, et al. Targeteddisruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol. 2000;156(3):1073–83.
- Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779–792.
- Shandling AH, Ellestad MH, Hart GB, Crump R, Marlow D, Van Natta B, et al. Hyperbaric oxygen and thrombolysis in myocardial infarction: the “HOT MI” pilot study. Am Heart J. 1997;134(3):544–550.
- Dekleva M, Neskovic A, Vlahovic A, Putnikovic B, Beleslin B, Ostojic M. Adjunctive effect of hyperbaric oxygen treatment after thrombolysis on left ventricular function in patients with acute myocardial infarction. Am Heart J. 2004;148(4):589.
- Sterling DL, Thornton JD, Swafford A, Gottlieb SF, Bishop SP, Stanley AW, et al. Hyperbaric oxygen limits infarct size in ischemic rabbit myocardium in vivo. Circulation. 1993;88:1931–6.
- Tahep IDP, Valen G, Starkopf J, Kairane C, Zilmer M, Vaage J. Pretreating rats with hyperoxia attenuates ischemia–reperfusion injury of the heart. Life Sci. 2001;68:1629–40.
- Khan M, Meduru S, Mohan IK, Kuppusamy ML, Wisel S, Kulkarni A, et al. Hyperbaric oxygenation enhances transplanted cell graft and functional recovery in the infarct heart. J Mol Cell Cardiol. 2009 Aug;47(2):275–87.
- Cabigas BP, Su J, Hutchins W, Shi Y, Schaefer RB, Recinos RF, et al. Hyperoxic and hyperbaric-induced cardioprotection: role of nitric oxide synthase 3. Cardiovasc Res. 2006;72(1):143–51.